---
document_datetime: 2025-12-29 13:33:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fasenra.html
document_name: fasenra.html
version: success
processing_time: 0.1171671
conversion_datetime: 2025-12-30 00:16:36.427853
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fasenra

[RSS](/en/individual-human-medicine.xml/65831)

##### Authorised

This medicine is authorised for use in the European Union

benralizumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fasenra](#news-on)
- [More information on Fasenra](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fasenra is an asthma medicine used to treat adults with a particular type of asthma called eosinophilic asthma. It is used as an additional treatment in adults with severe asthma that is not adequately controlled by a combination of high-dose inhaled corticosteroids plus medicines called long-acting beta-agonists. Fasenra contains the active substance benralizumab.

Expand section

Collapse section

## How is Fasenra used?

Fasenra is available as a solution for injection in pre-filled syringes and pre-filled pens. It can only be obtained with a prescription and treatment should be started by doctors with experience in the diagnosis and treatment of severe asthma.

The recommended dose is 30 mg injected under the skin of the thighs or belly every 4 weeks for the first 3 doses, and every 8 weeks afterwards. If the injection is given by a doctor or carer, it can also be given under the skin of the upper arm. If agreed with the treating doctor, patients already using Fasenra and with no history of severe allergic reactions, or their carers, can inject Fasenra themselves after proper training, including on how to watch out for signs and symptoms of allergic reactions. Fasenra should be given for as long as the patient benefits from it, and doctors should re-assess at least once a year whether treatment should be continued.

For more information about using Fasenra, see the package leaflet or contact your doctor or pharmacist.

## How does Fasenra work?

In eosinophilic asthma, symptoms are associated with having too many of a type of white blood cell called eosinophils in the blood and in phlegm in the lungs. The active substance in Fasenra, benralizumab, is a monoclonal antibody (a type of protein) designed to attach to receptors (targets) called interleukin-5 receptors on the surface of eosinophils. By attaching to interleukin-5 receptors, Fasenra activates the immune system (the body's natural defences) to kill the eosinophils in the blood and lungs. This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms.

## What benefits of Fasenra have been shown in studies?

Fasenra was shown to reduce the number of exacerbations (flare-ups) of asthma during treatment in 2 main studies involving a total of 2,511 patients with eosinophilic asthma that was not adequately controlled by a combination of high-dose inhaled corticosteroids and long-acting beta-agonists. Among patients with the highest number of blood eosinophils before treatment, the number of severe flare-ups per year was 0.66 in patients treated with Fasenra (given every 4 weeks for the first 3 doses and every 8 weeks afterwards), compared with 1.14 in patients given placebo (a dummy treatment).

A third study involving 220 patients showed that more patients given Fasenra had their condition improved to the extent that they could reduce their dose of corticosteroids by an average of 75% compared with 25% of those given placebo.

## What are the risks associated with Fasenra?

The most common side effects with Fasenra (which may affect up to 1 in 10 people) include headache and pharyngitis (sore throat). For the full list of side effects and restrictions of Fasenra, see the package leaflet.

## Why is Fasenra authorised in the EU?

Fasenra has been shown to be more effective than placebo at reducing the number of asthma flare-ups and the need for corticosteroid treatment. The medicine is well tolerated with few side effects. The European Medicines Agency therefore decided that Fasenra's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fasenra?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fasenra have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fasenra are continuously monitored. Side effects reported with Fasenra are carefully evaluated and any necessary action taken to protect patients.

## Other information about Fasenra

Fasenra received a marketing authorisation valid throughout the EU on 8 January 2018.

Fasenra : EPAR - Medicine overview

Reference Number: EMA/408482/2019

English (EN) (68.26 KB - PDF)

**First published:** 08/03/2018

**Last updated:** 27/08/2019

[View](/en/documents/overview/fasenra-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-294)

български (BG) (117.84 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/bg/documents/overview/fasenra-epar-medicine-overview_bg.pdf)

español (ES) (95.66 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/es/documents/overview/fasenra-epar-medicine-overview_es.pdf)

čeština (CS) (113.91 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/cs/documents/overview/fasenra-epar-medicine-overview_cs.pdf)

dansk (DA) (94.53 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/da/documents/overview/fasenra-epar-medicine-overview_da.pdf)

Deutsch (DE) (96.11 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/de/documents/overview/fasenra-epar-medicine-overview_de.pdf)

eesti keel (ET) (92.93 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/et/documents/overview/fasenra-epar-medicine-overview_et.pdf)

ελληνικά (EL) (125.33 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/el/documents/overview/fasenra-epar-medicine-overview_el.pdf)

français (FR) (104.04 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/fr/documents/overview/fasenra-epar-medicine-overview_fr.pdf)

hrvatski (HR) (109.22 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/hr/documents/overview/fasenra-epar-medicine-overview_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/it/documents/overview/fasenra-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (113.06 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/lv/documents/overview/fasenra-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (112.87 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/lt/documents/overview/fasenra-epar-medicine-overview_lt.pdf)

magyar (HU) (108.67 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/hu/documents/overview/fasenra-epar-medicine-overview_hu.pdf)

Malti (MT) (114.05 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/mt/documents/overview/fasenra-epar-medicine-overview_mt.pdf)

Nederlands (NL) (95.79 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/nl/documents/overview/fasenra-epar-medicine-overview_nl.pdf)

polski (PL) (113.82 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/pl/documents/overview/fasenra-epar-medicine-overview_pl.pdf)

português (PT) (95.67 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/pt/documents/overview/fasenra-epar-medicine-overview_pt.pdf)

română (RO) (112.08 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/ro/documents/overview/fasenra-epar-medicine-overview_ro.pdf)

slovenčina (SK) (112.87 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/sk/documents/overview/fasenra-epar-medicine-overview_sk.pdf)

slovenščina (SL) (108.14 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/sl/documents/overview/fasenra-epar-medicine-overview_sl.pdf)

Suomi (FI) (94.35 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/fi/documents/overview/fasenra-epar-medicine-overview_fi.pdf)

svenska (SV) (94.28 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/sv/documents/overview/fasenra-epar-medicine-overview_sv.pdf)

Fasenra : EPAR - Risk Management Plan

English (EN) (1.8 MB - PDF)

**First published:** 14/02/2025

**Last updated:** 27/02/2025

[View](/en/documents/rmp/fasenra-epar-risk-management-plan_en.pdf)

## Product information

Fasenra : EPAR - Product Information

English (EN) (1.36 MB - PDF)

**First published:** 08/03/2018

**Last updated:** 14/02/2025

[View](/en/documents/product-information/fasenra-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-358)

български (BG) (1.49 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/bg/documents/product-information/fasenra-epar-product-information_bg.pdf)

español (ES) (1.29 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/es/documents/product-information/fasenra-epar-product-information_es.pdf)

čeština (CS) (1.48 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/cs/documents/product-information/fasenra-epar-product-information_cs.pdf)

dansk (DA) (1.11 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/da/documents/product-information/fasenra-epar-product-information_da.pdf)

Deutsch (DE) (1.29 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/de/documents/product-information/fasenra-epar-product-information_de.pdf)

eesti keel (ET) (1.34 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/et/documents/product-information/fasenra-epar-product-information_et.pdf)

ελληνικά (EL) (1.05 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/el/documents/product-information/fasenra-epar-product-information_el.pdf)

français (FR) (1.01 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/fr/documents/product-information/fasenra-epar-product-information_fr.pdf)

hrvatski (HR) (972.13 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/hr/documents/product-information/fasenra-epar-product-information_hr.pdf)

íslenska (IS) (1.36 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/is/documents/product-information/fasenra-epar-product-information_is.pdf)

italiano (IT) (1.38 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/it/documents/product-information/fasenra-epar-product-information_it.pdf)

latviešu valoda (LV) (1.13 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/lv/documents/product-information/fasenra-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1018.03 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/lt/documents/product-information/fasenra-epar-product-information_lt.pdf)

magyar (HU) (1.14 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/hu/documents/product-information/fasenra-epar-product-information_hu.pdf)

Malti (MT) (1.36 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/mt/documents/product-information/fasenra-epar-product-information_mt.pdf)

Nederlands (NL) (1.46 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/nl/documents/product-information/fasenra-epar-product-information_nl.pdf)

norsk (NO) (1.38 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/no/documents/product-information/fasenra-epar-product-information_no.pdf)

polski (PL) (1.41 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/pl/documents/product-information/fasenra-epar-product-information_pl.pdf)

português (PT) (1.28 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/pt/documents/product-information/fasenra-epar-product-information_pt.pdf)

română (RO) (1.47 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/ro/documents/product-information/fasenra-epar-product-information_ro.pdf)

slovenčina (SK) (1.3 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/sk/documents/product-information/fasenra-epar-product-information_sk.pdf)

slovenščina (SL) (1.45 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/sl/documents/product-information/fasenra-epar-product-information_sl.pdf)

Suomi (FI) (911.7 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/fi/documents/product-information/fasenra-epar-product-information_fi.pdf)

svenska (SV) (1.31 MB - PDF)

**First published:**

08/03/2018

**Last updated:**

14/02/2025

[View](/sv/documents/product-information/fasenra-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0054 13/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fasenra : EPAR - All Authorised presentations

English (EN) (22.99 KB - PDF)

**First published:** 08/03/2018

**Last updated:** 27/08/2019

[View](/en/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-772)

български (BG) (24.29 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/bg/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_bg.pdf)

español (ES) (22.5 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/es/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_es.pdf)

čeština (CS) (23.48 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/cs/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.66 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/da/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.78 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/de/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.09 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/et/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (28.66 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/el/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_el.pdf)

français (FR) (22.61 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/fr/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (21.84 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/hr/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (23.92 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/is/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_is.pdf)

italiano (IT) (21.04 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/it/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (23.3 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/lv/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (23 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/lt/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (43.08 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/hu/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (23.31 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/mt/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.55 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/nl/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.45 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/no/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.93 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/pl/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.73 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/pt/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_pt.pdf)

română (RO) (26.68 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/ro/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (23.34 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/sk/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.75 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/sl/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.62 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/fi/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (22.96 KB - PDF)

**First published:**

08/03/2018

**Last updated:**

27/08/2019

[View](/sv/documents/all-authorised-presentations/fasenra-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fasenra Active substance Benralizumab International non-proprietary name (INN) or common name benralizumab Therapeutic area (MeSH) Asthma Anatomical therapeutic chemical (ATC) code R03DX10

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Asthma Fasenra is indicated as an add on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long acting β agonists (see section 5.1). Eosinophilic granulomatosis with polyangiitis (EGPA) Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004433 Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 09/11/2017 Marketing authorisation issued 08/01/2018 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fasenra : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (241.22 KB - PDF)

**First published:** 18/05/2018

**Last updated:** 27/02/2025

[View](/en/documents/procedural-steps-after/fasenra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fasenra-H-C-004433-II-0052 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/598631/2024

English (EN) (2.92 MB - PDF)

**First published:** 14/02/2025

[View](/en/documents/variation-report/fasenra-h-c-004433-ii-0052-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Fasenra (II-52)

Adopted

Reference Number: EMA/422937/2024

English (EN) (129.61 KB - PDF)

**First published:** 20/09/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fasenra-ii-52_en.pdf)

Fasenra-H-C-004433-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/499801/2023

English (EN) (1.6 MB - PDF)

**First published:** 08/11/2023

[View](/en/documents/variation-report/fasenra-h-c-004433-p46-008-epar-assessment-report_en.pdf)

Fasenra-H-C-004433-P46-007 : EPAR - Assessment Report

Adopted

Reference Number: EMA/183609/2023

English (EN) (1.57 MB - PDF)

**First published:** 25/05/2023

[View](/en/documents/variation-report/fasenra-h-c-004433-p46-007-epar-assessment-report_en.pdf)

Fasenra-H-C-004433-P46 : EPAR - Assessment Report

Adopted

Reference Number: EMA/622026/2018

English (EN) (1.22 MB - PDF)

**First published:** 16/10/2018

[View](/en/documents/variation-report/fasenra-h-c-004433-p46-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Fasenra : EPAR - Public assessment report

Adopted

Reference Number: EMA/780390/2017

English (EN) (2.39 MB - PDF)

**First published:** 08/03/2018

**Last updated:** 08/03/2018

[View](/en/documents/assessment-report/fasenra-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fasenra

Adopted

Reference Number: EMA/727638/2017

English (EN) (120.68 KB - PDF)

**First published:** 10/11/2017

**Last updated:** 10/11/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fasenra_en.pdf)

#### News on Fasenra

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2024) 20/09/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2017) 10/11/2017

#### More information on Fasenra

- [EMEA-001214-PIP01-11-M11 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip01-11-m11)
- [EMEA-001214-PIP06-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip06-20)
- [EMEA-001214-PIP05-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip05-19)
- [EMEA-001214-PIP08-21 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip08-21)
- [EMEA-001214-PIP09-21-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip09-21-m01)
- [EMEA-001214-PIP04-19-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip04-19-m01)
- [EMEA-001214-PIP07-21 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001214-pip07-21)
- [Impact of biologics on inhaled corticosteroids reduction (MOON LIGHT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000855)
- [Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000788)
- [Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000789)
- [Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000530)
- [Descriptive Study of the Incidence of Malignancy in Patients with Severe Asthma Overall and Among Those Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study - post-authorisation study](https://catalogues.ema.europa.eu/study/50719)
- [Associations between biological and clinical response following treatment with anti-IL5/5R biologics (FLAME) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000531)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/02/2025

## Share this page

[Back to top](#main-content)